Medarex Studying Ipilimumab As First-Line Treatment For Metastatic Melanoma
The registrational trial will compare patients treated with ipilimumab and decarbazine with decarbazine alone.
The registrational trial will compare patients treated with ipilimumab and decarbazine with decarbazine alone.